Hypercholesterolemia

FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia

... inhibitor (statin), for the primary treatment of hypercholesterolemia and combined dyslipidemia. "The approval ... attractive alternative for patients with primary hypercholesterolemia or combined dyslipidemia," said Antonio M. Gotto ... used in these countries to treat primary hypercholesterolemia and combined dyslipidemia, and has accumulated ...

Isis Reports Strong Financial Results and Highlights for First Quarter of 2009

... evaluating mipomersen in homozygous Familial hypercholesterolemia (FH) patients and from additional mipomersen ... evaluating mipomersen in homozygous Familial hypercholesterolemia patients. We expect top-line data from this ... a Phase 3 study evaluating mipomersen in severe hypercholesterolemia patients. This latest mipomersen study is the ...

Isis Reports Strong Financial Results and Highlights for Fiscal Year 2008

... evaluating mipomersen in homozygous Familial hypercholesterolemia (FH) patients and from additional mipomersen ... 3 studies in heterozygous FH subjects, high-risk hypercholesterolemia and severe hypercholesterolemia patients and a Phase 2 study in statin-intolerant ...

GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.

... The results of a study in patients with primary hypercholesterolemia are presented in Table I. ... The study was performed with patients with hypercholesterolemia who were at high risk of myocardial infarction. ... with Heterozygous Familial hypercholesterolemia (Mean Percent Change from Baseline at week 48 ...

Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months

... study of ISIS 301012 in patients with familial hypercholesterolemia (FH) on stable maximally tolerated lipid-lowering ... mg/week as its development dose. About Familial hypercholesterolemia Familial hypercholesterolemia is a genetic condition that results in markedly ...

Children May Have Cholesterol Problems, Too

... have a genetic predisposition for excess cholesterol levels -- familial hypercholesterolemia (FH). These children have high levels of low-density lipoprotein (LDL), ... disease and an increased risk of early heart attack. Familial hypercholesterolemia is underestimated in the community and in pediatric primary care ....

Genes Linked to Cholesterol in Cells Are Identified

... some of the genes identified by us as regulators of cellular cholesterol in future studies might turn out to be disease genes that contribute to hypercholesterolemia [high cholesterol] in some cases." The genes identified in the study may also have potential as targets for new cholesterol-lowering drugs, the ...

Sanofi-aventis Announces Good First-quarter 2009 Performance

... Phase III, saredutant is discontinued on the basis of results from the study in association with escitalopram in depression, AVE5530 is halted in hypercholesterolemia due to insufficient efficacy, and the rights to TroVax (R) are returned to Oxford BioMedica. As regards vaccines, resources in the intercontinental ...

BioMed Realty Trust's Center for Life Science Boston Now 91% Leased

... business, Kowa is responsible for sales and marketing of innovative drugs and focuses on promoting cardiovascular drugs, such as a treatment drug for hypercholesterolemia and hypertension through its owned subsidiary, Kowa Pharmaceutical Co. Ltd. In addition, Kowa has focused on lifestyle diseases (arteriosclerosis, ...

Studies Challenge Framingham Risk Score

... Risk Score is validated up to age 75. There have been signs in the medical literature that the classic risk factors such as hypertension and hypercholesterolemia [high cholesterol levels] were not performing that well for people with advanced age." The new study "indicates that the traditional risk factors ...

Hypercholesterolemia in Medical Technology

Study Demonstrates Efficacy of Pitavastatin in Elderly Patients

... in a group of elderly patients with primary hypercholesterolemia or combined dyslipidemia," said Professor Steen ... aged more than or equal to 65 years with primary hypercholesterolemia or combined dyslipidemia. About half of the ... suitable statin for elderly patients with primary hypercholesterolemia or combined dyslipidemia who are taking other ...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... data from a Phase 3 study evaluating mipomersen in homozygous Familial hypercholesterolemia (FH) patients; positive top line data was reported in May 2009 ... in Europe shortly afterwards. Data from our Phase 3 study in severe hypercholesterolemia patients should be available at the time of these U.S. submissions and may ...

New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer

... with interferon-alpha. TORISEL also was associated with the development of hypercholesterolemia of grade 2 or higher, compared with interferon-alpha (P=0.001), but there ... interferon-alpha (P=0.675). However, the development of hyperglycemia or hypercholesterolemia did not have affect on overall survival or progression-free survival in ...

Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months

... 2 open-label extension (OLE) study of mipomersen in patients with familial hypercholesterolemia (FH). In FH patients exposed to mipomersen for as long as 16 months, the ... high cholesterol at high risk of cardiovascular events. ABOUT FAMILIAL hypercholesterolemia (FH) FH patients have high blood concentrations of LDL-cholesterol due ...

New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease

... to prevent heart disease, heart attacks, or strokes. For patients with hypercholesterolemia and mixed dyslipidemia, the usual recommended starting dose of CRESTOR is ... and patients with severe renal insufficiency. For patients with marked hypercholesterolemia (LDL-C >190 mg/dL) and aggressive lipid targets, a 20-mg starting dose may ...

New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure

... to prevent heart disease, heart attacks, or strokes. For patients with hypercholesterolemia and mixed dyslipidemia, the usual recommended starting dose of CRESTOR is ... and patients with severe renal insufficiency. For patients with marked hypercholesterolemia (LDL-C >190 mg/dL) and aggressive lipid targets, a 20-mg starting dose may ...

Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients

... has selected 200 mg/week as its development dose. About Familial hypercholesterolemia Familial hypercholesterolemia is a genetic condition that results in markedly elevated LDL-C levels ...

Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination

... to prevent heart disease, heart attacks, or strokes. For patients with hypercholesterolemia and mixed dyslipidemia, the usual recommended starting dose of CRESTOR is ... and patients with severe renal insufficiency. For patients with marked hypercholesterolemia (LDL-C>190 mg/dL) and aggressive lipid targets, a 20-mg starting dose may ...

Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

... significant reduction in low density lipoprotein (LDL) or "bad" cholesterol when used as monotherapy or in combination with a statin. Familial hypercholesterolemia (FH) is a genetic disorder resulting in elevated LDL cholesterol and increased risk of cardiovascular disease (CVD).(1) There are 10 million people ...

Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen

... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced that they have begun a phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH), a genetic disorder that causes exceptionally high levels of LDL cholesterol. It is the first of four new trials the companies plan to ...

Hypercholesterolemia in Medical Definition

Pathology

... ) Other lipid Lipoprotein/lipidemias: Hyperlipidemia - hypercholesterolemia - Familial hypercholesterolemia - Xanthoma - Combined hyperlipidemia - Lecithin cholesterol ...

Hypercholesterolemia in Medical Dictionary

Familial Hypercholesterolemia

... Familial hypercholesterolemia : The most common inherited type of ... One in every 500 children is born with familial hypercholesterolemia . Familial hypercholesterolemia Definition: A dominantly inherited genetic ...

Beta

... Insensitivity Syndrome ( Testicular Feminization ) Enzymatic Disorders ( Inborn Errors of Metabolism ) Familial Combined Hyperlipidemia Familial hypercholesterolemia ... Beta Carotene Based on solid evidence, high-intensity smokers who take pharmacological doses of beta carotene have an increased ...

Dysautonomia

... Lipase Deficiency ) Familial Combined Hyperlipidemia Familial Dysautonomia ( Riley-Day Syndrome ) Familial Dysbetalipoproteinemia Familial hypercholesterolemia ... ...

Familial Dysautonomia

... Lipase Deficiency ) Familial Combined Hyperlipidemia Familial Dysautonomia ( Riley-Day Syndrome ) Familial Dysbetalipoproteinemia Familial hypercholesterolemia ... ...

HDL

... elevated total cholesterol , LDL cholesterol , apo B, and triglyceride level s and to increase HDL cholesterol in patients with primary hypercholesterolemia (heterozygous, ... Most important, it boosts the amount of HDL ("good") cholesterol in the blood . This compound helps prevent the buildup of ...

Hermaphroditism

... ) Metabolic Disorders ( Inborn Errors of Metabolism ) Muscular Dystrophy Testicular Feminization Type IIa Hyperlipoproteinemia ( Familial hypercholesterolemia ) ... ...

Hypercoagulable states

... , consequences, ... Hypercalcemia Hypercalciuria - Idiopathic ( Idiopathic Hypercalciuria) Hypercholesterolemic Xanthoma tosis ( Familial hypercholesterolemia ) Hypercoagulable States Hypercortisolism (Cushing's Syndrome ) ... ...

LDL

... elevated total cholesterol , LDL cholesterol , apo B, and triglyceride level s and to increase HDL cholesterol in patients with primary hypercholesterolemia (heterozygous, ... However, the British Heart Association recommends a target for LDL - cholesterol of 2.5 mmol/l and European guidelines are ...

Lipoprotein

... blood : ... Lescol (fluvastatin sodium ) New indication: reduction of triglycerides and apo lipoprotein B (Apo B) in patients with primary hypercholesterolemia and mixed dyslipidemia (both elevated cholesterol and triglycerides). After drawing a vial of blood , a lab will determine the amount of ...

Triglyceride level

... elevated total cholesterol , LDL cholesterol , apo B, and triglyceride level s and to increase HDL cholesterol in patients with primary hypercholesterolemia (heterozygous, ... Triglyceride level s are influenced by recent fat and alcohol intake, so you should fast from food for at least 12 hours ...

More>>

Hypercholesterolemia in Biological Technology

Genzyme Launches Cholestagel(R) in Europe

... New Therapy Helps Lower Cholesterol in Primary hypercholesterolemia Patients ... as an add-on therapy in patients with familial hypercholesterolemia (FH) -- an inherited disorder that causes ... with peripheral arterial disease. About Primary hypercholesterolemia ...

Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen

... under the Hart-Scott-Rodino Antitrust Improvements Act. About Familial hypercholesterolemia (FH) FH patients have high blood concentrations of LDL-cholesterol due ... of premature cardiovascular diseases (CVD) and CVD-related death. Familial hypercholesterolemia can be present in two forms: homozygous (hoFH), where the same defective ...

Isis Reports Financial Results and Highlights for Third Quarter of 2008

... and high-risk high cholesterol patients -- Report top line data on mipomersen from a Phase 2 liver imaging study in heterozygous Familial hypercholesterolemia (FH) patients -- Provide an update on mipomersen from an ongoing open-label extension study in patients with FH -- Report Phase 2 study data in ...

Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)

... to lower Total-C and LDL-C to target levels. CRESTOR has not been determined to prevent heart disease, heart attacks, or strokes. For patients with hypercholesterolemia and mixed dyslipidemia, the usual recommended starting dose of CRESTOR is 10 mg. The 40-mg dose of CRESTOR is reserved only for those patients who ...

Isis Reports Financial Results and Highlights for Second Quarter of 2008

... performance." Upcoming Key Milestones -- Initiate three trials in addition to the Phase 3 study in patients with heterozygous Familial hypercholesterolemia (FH) announced this week, studying mipomersen in apheresis-eligible patients and high-risk high cholesterol patients -- Present liver ...

Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management

... has been inadequate, to reduce elevated total cholesterol, LDL- C, Apo B, and triglyceride levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. In patients with a history of myocardial infarction and hypercholesterolemia, niacin is indicated to reduce the risk of ...

Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy

... in the prevention of coronary disease, the nation's top killer. "Atherotech believes that precise physician decisions about lifelong management of hypercholesterolemia can only be accomplished with a detailed profiling of lipoprotein components," said Atherotech Chief Medical Officer James Ehrlich, M.D. "By ...

Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections

... in the treatment of diseases, the etiology of which is misrouted or misfolded proteins, for example, cystic fibrosis, nephrogenic diabetes insipidus, hypercholesterolemia and others. Axentis is managed by a team of experienced entrepreneurs. About aRigen Pharmaceuticals, Inc. ( http://www.arigen.jp ) aRigen ...

New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition

... alone or in combination with a statin, as an adjunct to diet and exercise for the reduction of elevated LDL cholesterol in patients with primary hypercholesterolemia (Fredrickson Type IIa) when the response to diet and exercise has been inadequate. Liver- function monitoring is not required with WelChol when used ...